Biomarin Pharmaceutical Stock Working Capital
| BMRN Stock | USD 71.24 0.36 0.50% |
Biomarin Pharmaceutical fundamentals help investors to digest information that contributes to Biomarin Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Biomarin Stock. The fundamental analysis module provides a way to measure Biomarin Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biomarin Pharmaceutical stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 2.6 B | 1.9 B | |
| Change In Working Capital | -216.4 M | -205.6 M |
Biomarin | Working Capital |
Biomarin Pharmaceutical Company Working Capital Analysis
Biomarin Pharmaceutical's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Biomarin Pharmaceutical Working Capital | 2.63 B |
Most of Biomarin Pharmaceutical's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomarin Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Biomarin Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Biomarin Pharmaceutical is extremely important. It helps to project a fair market value of Biomarin Stock properly, considering its historical fundamentals such as Working Capital. Since Biomarin Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biomarin Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biomarin Pharmaceutical's interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Biomarin Capital Surpluse
Capital Surpluse |
|
In accordance with the company's disclosures, Biomarin Pharmaceutical has a Working Capital of 2.63 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is 77.61% lower than that of the firm.
Biomarin Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biomarin Pharmaceutical's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biomarin Pharmaceutical could also be used in its relative valuation, which is a method of valuing Biomarin Pharmaceutical by comparing valuation metrics of similar companies.Biomarin Pharmaceutical is currently under evaluation in working capital category among its peers.
Biomarin Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Biomarin Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Biomarin Pharmaceutical's managers, analysts, and investors.Environmental | Governance | Social |
Biomarin Fundamentals
| Return On Equity | 0.0805 | ||||
| Return On Asset | 0.0515 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.34 % | ||||
| Current Valuation | 13.12 B | ||||
| Shares Outstanding | 190.78 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 98.62 % | ||||
| Number Of Shares Shorted | 4.47 M | ||||
| Price To Earning | 220.73 X | ||||
| Price To Book | 2.41 X | ||||
| Price To Sales | 4.79 X | ||||
| Revenue | 2.85 B | ||||
| Gross Profit | 2.27 B | ||||
| EBITDA | 650.53 M | ||||
| Net Income | 426.86 M | ||||
| Cash And Equivalents | 1.27 B | ||||
| Cash Per Share | 6.85 X | ||||
| Total Debt | 602.71 M | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 29.66 X | ||||
| Cash Flow From Operations | 572.84 M | ||||
| Short Ratio | 2.98 X | ||||
| Earnings Per Share | 2.21 X | ||||
| Price To Earnings To Growth | 0.49 X | ||||
| Target Price | 96.72 | ||||
| Number Of Employees | 3.04 K | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 13.66 B | ||||
| Total Asset | 6.99 B | ||||
| Retained Earnings | (194.69 M) | ||||
| Working Capital | 2.63 B | ||||
| Current Asset | 1.09 B | ||||
| Current Liabilities | 445.46 M | ||||
| Net Asset | 6.99 B |
About Biomarin Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biomarin Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biomarin Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biomarin Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock: Check out Biomarin Pharmaceutical Piotroski F Score and Biomarin Pharmaceutical Altman Z Score analysis. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.21 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.